 |
|
|
| |
HDV-RNA decline less than 1 log after 6 months of BLV 2 mg monotherapy could define poor-response and lead to therapeutic decision. Data from real-life cohort
|
| |
| |
EASL 2023 June 23 Vienna
Victor de Lédinghen1, Edouard Bardou-Jacquet2, Sophie Metivier3,3, Nathalie Ganne-Carrié4, Veronique Loustaud-Ratti5,
Marie-Noëlle Hilleret6, Laurent Alric3, Anne Minello Franza7,
Tarik Asselah4, Dominique Roulot4, Isabelle Fouchard Hubert8, Stanislas Pol4, Bruno Roche4, Valérie Canva9, Xavier Causse10, Anne Gervais4, Frederic Heluwaert11, Jérôme Dumortier12,
Karine Lacombe4, Caroline Lascoux-Combe4, Louis d'Alteroche13, Patrick Miailhes14, Leon Muti15, Isabelle Ollivier-Hourmand16, Christiane Stern4, Isabelle Rosa17, Fabien Zoulim18, Juliette Foucher1.
|
| |
|
|
|
|
|
